Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.64 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | VDR | P11473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9005930 | 0.87 | ALDH1A1 (0.50) | PPARGALDH1A1TP53DRD4 | |
| SCHEMBL9005904 | 0.82 | DRD4 (0.46) | PPARGRAB9ATP53DRD4 | |
| SCHEMBL7926603 | 0.82 | PPARG (0.50) | PPARGPPARD | |
| SCHEMBL7920692 | 0.82 | PPARG (0.50) | PPARGLTA4HPPARD | |
| SCHEMBL9005955 | 0.81 | ALOX5 (0.47) | PPARGLTA4HTP53DRD4 | |
| SCHEMBL7920667 | 0.80 | PPARG (0.42) | PPARGLTA4HALDH1A1RAB9ADRD4 | |
| SCHEMBL2786491 | 0.80 | PPARG (0.53) | PPARGDRD4 | |
| SCHEMBL9160316 | 0.79 | PPARG (0.42) | PPARGTP53DRD4 | |
| SCHEMBL7922719 | 0.79 | PPARG (0.48) | PPARGDRD4 | |
| SCHEMBL4744464 | 0.79 | ATP4A (0.45) | RAB9ATP53DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | disclosed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | disclosed |